Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines

被引:7
|
作者
Mahboobi, H
Viarengo, A
Colangelo, D
Osella, D
机构
[1] Univ Piemonte Orientale, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy
[2] Univ Piemonte Orientale, Dipartimento Sci Med, I-28100 Novara, Italy
关键词
chemoresistance; metal-based anticancer drugs; metallothionein; mouse embryo fibroblasts;
D O I
10.1023/A:1022586310104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metallothioneins (MT) are ubiquitous low-molecular-weight metal-binding intracellular proteins. We used wild type mouse embryo fibroblasts, GKA1, and its MT-null variant, named GKA2, in order to correlate the presence of MT to the response to a number of different antitumor drugs with different mechanisms of action. We studied sensitivity of GKA1 and GKA2 cells to metal-based compounds having alkylating property, or able to generate reactive oxygen species (ROS); as well as to drugs acting with different mechanisms. The absence of MT in GKA2 cells was correlated to higher sensitivity to the metal-based drugs compared to that of GKA1. No marked differences in sensitivity of two cell lines against gemcitabine, taxol, and vinblastine were observed. No significant change in sensitivity of either GKA1 or GKA2 cells to these non-alkylating drugs was seen after heavy metal pretreatments. In GKA1 cells, MT biosynthesis was induced by copper and cadmium but not by zinc treatment under the conditions of these experiments. Induction of MT was directly proportional to decrease in sensitivity of GKA1 cells to the compounds used in this experiment. In contrast to GKA1 cells, the MT-null cells (GKA2) expressed no detectable metallothionein either constitutively or after treatment with zinc, copper, or cadmium. Nonetheless, heavy metal pretreatment of GKA2 cells did not cause any change in their sensitivity.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 50 条
  • [1] Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines
    H. Mahboobi
    A. Viarengo
    D. Colangelo
    D. Osella
    [J]. Biometals, 2003, 16 : 403 - 409
  • [2] Gold complexes as prospective metal-based anticancer drugs
    Milacic, V.
    Fregona, D.
    Dou, Q. P.
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 2008, 23 (01) : 101 - 108
  • [3] Polymeric Prodrugs Containing Metal-Based Anticancer Drugs
    B. A. Aderibigbe
    [J]. Journal of Inorganic and Organometallic Polymers and Materials, 2015, 25 : 339 - 353
  • [4] Polymeric Prodrugs Containing Metal-Based Anticancer Drugs
    Aderibigbe, B. A.
    [J]. JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS, 2015, 25 (03) : 339 - 353
  • [5] A New Look into the Mode of Action of Metal-Based Anticancer Drugs
    Marques, M. Paula M.
    de Carvalho, Ana L. M. Batista
    Mamede, Adriana P.
    Dopplapudi, Asha
    Rudic, Svemir
    Tyagi, Madhusudan
    Sakai, Victoria Garcia
    Batista de Carvalho, Luis A. E.
    [J]. MOLECULES, 2020, 25 (02):
  • [6] Electron-transfer activated metal-based anticancer drugs
    Reisner, Erwin
    Arion, Vladimir B.
    Keppler, Bernhard K.
    Pombeiro, Armando J. L.
    [J]. INORGANICA CHIMICA ACTA, 2008, 361 (06) : 1569 - 1583
  • [7] Supramolecular Delivery Systems for NonPlatinum Metal-Based Anticancer Drugs
    Ringhieri, Paola
    Morelli, Giancarlo
    Accardo, Antonella
    [J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2017, 34 (02): : 149 - 183
  • [8] New Strategies and Trends for the Design of Metal-Based Anticancer Drugs
    Wang Xiaoyong
    Guo Zijian
    [J]. PROGRESS IN CHEMISTRY, 2009, 21 (05) : 845 - 855
  • [9] The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions
    Bergamo, Alberta
    Dyson, Paul J.
    Sava, Gianni
    [J]. COORDINATION CHEMISTRY REVIEWS, 2018, 360 : 17 - 33
  • [10] Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
    Bergamo, Alberta
    Sava, Gianni
    [J]. DALTON TRANSACTIONS, 2011, 40 (31) : 7817 - 7823